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ABSTRACT
Basaloid squamous cell carcinoma (BSCC) is a rare, aggressive and distinct 
variant of squamous cell carcinoma (SCC) of the upper respiratory and digestive tract. 
We have evaluated disease specific survival (DSS) and overall survival (OS) through 
Kaplan-Meier method and mortality risk through univariate statistical analysis of Cox 
in 42 cases of BSCC and other 42 of laryngeal SCC (LSCC) matched for both age and 
sex. We demonstrated that laryngeal BSCC is a more aggressive tumor than LSCC as is 
associated to higher nodal recurrence of pathology (5 vs 2 patients, median survival, 
OR 2.7), a reduced survival (median survival 34 vs 40 months, OR 3.2 for mortality); 
in addition, basaloid patients have a higher risk to be affected by second primary 
tumors (13 vs 3 patients, OR 5.8) and a higher probability to die for this second 
tumor (Hazard Risk, HR 4.4). The analysis of survival shows an increased mortality 
risk concurrent with the parameters assessed by univariate analyses that assume a 
predictive and statistical significance in second tumor and grading in basaloid LSSC.
INTRODUCTION
Basaloid squamous cell carcinoma (BSCC) is a 
high-grade variant of squamous cell carcinoma (SCC) 
of the upper respiratory and digestive tract [1-4]. It was 
firstly described in 1986 by Wain et al. as a distinct 
histological variant of SCC and recognized by the World 
Health Organization (WHO) as a peculiar entity in 1991 
[9]. This malignancy seems to have a predilection for the 
head and neck region, especially for supraglottic larynx, 
tongue and hypopharynx [2, 3], but it can also occur at 
other sites such as esophagus, lung, thymus, anus, penis 
and cervix [3, 4, 7]. SCC basaloid subtype represents less 
than 1% of laryngeal carcinomas; it affects mainly men 
in sixth or seventh decade of life, and differs from the 
common form of SCC with specific morphological and 
biological features [4, 5]. BSCC has a poor prognosis for 
its invasive growth pattern and for its frequent diagnosis in 
advanced stage characterized by cervical node metastases 
[4-7]. Metastases in loco-regional nodes are reported in 
64% of patients and visceral metastases (lung, liver, bone, 
brain and skin) in 44% of cases [10]. The diagnosis is 
often delayed so that reasonable treatment options are 
radical surgery, chemoradiation or radiation alone (5 
years survival is reported to be 17.5%) [11, 12]. In this 
study, we have analyzed the aggressiveness of laryngeal 
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BSCC in a group of 42 patients (basaloid subgroup A) 
compared with a homogeneous group of 42 patients 
affected by laryngeal SCC (non-basaloid subgroup B) 
evaluating survival through Kaplan-Meier method, 
mortality risk through univariate statistical analysis of 
Cox considering the following variables: staging, grading, 
second tumors and treatment strategy. Moreover, we 
have studied any significant variable influencing survival 
through a multivariate and Hazard Risk (HR) analysis. 
In addition, we have calculated the overall risk (OR) for 
second tumors, mortality, nodal recurrence of pathology 
(N Recurrence) and recurrence of tumor (T Recurrence).
RESULTS
Demographic and clinical characteristics of the 
patients
Study population was formed by 84 cases of 
laryngeal carcinoma (74M and 10F) divided into two 
subgroups: 42 cases of basaloid laryngeal squamous 
cellular carcinoma (LSCC) (A) and 42 cases of Non-
basaloid LSCC (B). Basaloid subgroup (A) was composed 
by 37 males and 5 females with a median age of 71 years 
(range: 37-86 years); non-basaloid subgroup (B) by 
37 males and 5 females with a median age of 71 years 
(range: 40-82 years). No differences were recorded in 
staging distribution between the two subgroups; in fact, 
in both subgroups 2 patients were stage I, 3 stage II, 20 
stage III and 17 stage IV according to VII edition of TNM 
[13], respectively. Also for histological grading data there 
were no differences between the two subgroups; in fact, 
no patient had a well differentiated carcinoma (G1), 6 
patients had a moderately differentiated (G2), 10 patients 
a G2-G3 and 26 a poorly differentiated carcinoma (G3), 
respectively. Treatment strategies were the following: 
5 patients underwent to cordectomy, 8 to a supraglottic 
laryngectomy, 5 to subtotal laryngectomy and 24 to a total 
laryngectomy, respectively. In all cases of open surgery 
we performed also a neck dissection. Follow-up was 
performed in all patients; in basaloid subgroup median 
follow-up was 38 months (95% CI: 30.72-48.00 months), 
in non-basaloid subgroup 42.50 months (95% CI: 32.72-
49.27 months). The analysis of follow-up did not show 
any statistically significant difference between these two 
subgroups (p= 0.77), using Wilcoxon/Mann-Whitney test 
for independent and non-parametric variables. Therefore, 
basaloid and non-basaloid subgroups were homogeneus 
for demographic features, staging, grading, treatment 
strategy and follow-up.
Clinical outcome of the patients
Survival analysis
In basaloid subgroup, 14 patients died for other 
diseases (including second tumours) and 7 for cancer 
originating in laryngeal site; the median survival was 34 
months in the first group of patients (deceasing for other 
diseases) and 47 months for patients deceased for cancer 
originating in laryngeal site, respectively. Analysis of 
the survival rate in this subgroup of patients (basaloid 
subgroup A) analyzed for death causes (other diseases 
vs cancer originating in laryngeal site) showed a not 
statistically significant p value (2.1575 Chi-square, p= 
0.1419; HR 1.8234; 95% CI 0.7872 to 5.3145) as shown 
in Figure 1A. In non-basaloid subgroup B, 7 patients died 
for other diseases (including second tumours) and 3 for 
cancer originating in laryngeal site, respectively. Also 
in this subgroup the difference in the survival rate for 
death causes was not significant (0.3158 Chi-square, p= 
0.5742; HR 0.6914, 95% CI 0.1375 to 3.0038). In fact, 
median survival was 40 months for the first ones and 
38 months for patients deceased for cancer originating 
in laryngeal site, respectively (Figure 1B). Comparing 
the specific disease survival of the patients deceased for 
laryngeal cancer between basaloid (subgroup A) and non 
basaloid subgroups (subgroup B) we did not find again 
any statistically significant difference (2.1515 Chi-square, 
p= 0.1424; HR 0.5317 95% CI 0.1513 to 1.3123). Median 
survival was 48 months for subgroup A and 40 months 
for subgroup B, respectively. As second tumors were not 
considered in disease specific survival, this explains this 
apparent discordance (Figure 1C). Moreover, the overall 
survival between basaloid and not basaloid subgroup was 
not significantly statistically different. Median survival 
was 34 months for basaloid subgroup and 40 in non-
basaloid (0.8092 Chi-square, p= 0.3683; HR 1.3634 95% 
CI 0.6486 to 3.2140), respectively (Figure 2A). Figure 2B 
shows survival probability in relation to follow-up period 
in months in basaloid subgroup B. Cox proportional 
hazard model was used to verify if staging, grading, 
disease specific survival, treatment strategy and second 
tumors were independent prognostic factors both for 
basaloid LSCC patients (subgroup A) and for non-basaloid 
LSCC patients (subgroup B).
Univariate analysis showed that second tumor 
occurrence (HR 4.3634, p= 0.01583 for subgroup A and 
HR 3.9333, p= 0.07462 for subgroup B, respectively) and 
high G3 grading (HR 3.9333, p= 0.03 for subgroup A and 
HR 1.5246, p= 0.5533 for subgroup B, respectively), but 
not staging (HR 0.85, p= 0.62 for subgroup A and HR 
0.7911, p= 0.6302 for subgroup B, respectively), disease 
specific survival (HR 0.49, p= 0.15 for subgroup A and 
HR 1.507, p= 0.5768 for subgroup B, respectively) and 
treatment strategy (HR 0.8494, p= 0.45 for subgroup A 
and HR 0.6521, p= 0.1306 for subgroup B, respectively) 
correlated to decreased survival only in patients with 
basaloid LSCC (Table 1). Multivariate analysis of the 
same variables showed that again only second tumour 
occurrence had a statistically significant trend in 
correlating to poor prognosis score (p=0.07) while the 
grading was not statistically significant (p=0.29, HR for 
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Figure 1: Survival rate analysis in basaloid subgroup A (A); in non-basaloid subgroup B (B); disease specific survival 
comparison between two subgroups (C).
Figure 2: OS in basaloid A and non-basaloid B subgroups (A); survival probability in relation to follow-up period in months 
in basaloid subgroup B (B). 
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second tumor 3.18 and for grading HR 2.44, respectively) 
(Table 2). It was not possible to perform multiparametric 
analysis in LSCC because no variable was significant in 
univariate analysis.
DISCUSSION
BSCC was firstly described in 1986 by Wain et al., 
who reported 10 cases localized in the tongue, larynx and 
hypopharynx as a distinctive histological variant of SCC 
with aggressive behavior [9]. BSCC has been defined in 
the “2005 WHO blue book” as an aggressive high grade 
variant of SCC composed of both basaloid and squamous 
components [14] and it is believed to arise from a totipotent 
primitive cell in the basal layer of the surface epithelium 
or from the salivary duct lining epithelium [1, 15]. Upper 
aerodigestive tract is the most common site of origin of 
this tumor in the head and neck [15], especially larynx 
(supraglottic larynx in 68.6% of cases, epiglottis) [16], 
hypopharynx (piriform sinus), base of the tongue and less 
frequently the oropharynx (palatin tonsils) [1, 8, 15, 17]. A 
recent review of the literature shows that BSCC appears in 
both sexes but predominates in males (14:1) between 60 
and 80 years old [15]. The tumor shows the same strong 
association with tobacco and alcohol as conventional 
SCC [8, 15, 18]. It is still unclear the correlation with 
Epstein-Barr virus (EBV) and human papilloma virus 
(HPV) as a causal or contributory factor in BSCC [18]. 
Clinical signs and symptoms are not specific and related 
to tumor location [14]. The basaloid subtype of SCC is 
less than 1% of laryngeal carcinoma [1, 4]. The tumor 
can also occur at other sites such as the esophagus, lung, 
thymus, anus and cervix. Pathologically, BSCC has a 
distinctive biphasic histologic appearance, including 
basaloid and in situ or invasive SCC components [1, 19]. 
Some histological features such as nuclear pleomorphism, 
hyperchromasia, mitotic activity, necrosis and perineural 
invasion, when occurring all together indicate a high grade 
malignancy [7, 19]. By immunohistochemistry, BSCC 
expresses cytokeratins (AK1, AK3, LP34) and epithelial 
membrane antigen EMA [15]. Some authors recommend 
cocktails of keratins composed of CAM 5.2, pankeratin 
AE/AE3 and CK7, while others propose the high molecular 
weight keratin 34βE12 as the most useful marker for this 
tumor. There is no specific immunohistochemical pattern 
to distinguish this tumor from others. However, quite 
recently Coletta et al. have demonstrated the importance 
of cytokeratins 1, 7 and 14 in the diagnosis of BSCC and 
Emanuel et al. have stressed the value of p63 in making a 
distinction between BSCC and adenoid cystic carcinoma 
of the head and neck, showing that p63 positivity is diffuse 
in BSCC and partial in adenoid cystic carcinoma [15, 20, 
21]. The most important differential diagnosis for BSCC is 
the solid variant of adenoid cystic carcinoma and small cell 
neuroendocrine carcinoma [4]. Adenoid cystic carcinoma 
is positive for smooth muscle actin, whereas BSCC is 
negative; the latter has also greater reactivity for vimentin 
compared to BSCC [7]. Synaptophysin and chromogranin 
are positive in small cell neuroendocrine carcinoma, 
but are consistently negative in BSCC [4]. Kleist et al. 
and El-Mofty et al. have detected a higher frequency of 
Table 1: Demographic, clinical and pathological 
characteristics of enrolled patients
Variable Basaloid 
subgroup-A
Non-bas 
subgroup B
Median Age 71 y (37-86) 71 y (40-82)
Sex
 Male 37 37
 Female 5 5
Stage
I 2 2
II 3 3
III 20 20
IV 17 17
Grading
 G2 6 6
 G2-G3 10 10
 G3 26 26
Treatment strategy
 Cordectomy 4 5
 Supraglottic laryngectomy 8 8
 Subtotal laryngectomy 4 5
 Total laryngectomy 26 24
Second tumor occurrence 13 3
 Lung 6 2
 Colon 7 1
Death 21 10
Cause of death 21 patients 10 patients
 Laryngeal cancer 7 3
 Second tumor 12 3
 Other causes 2 4
Locoregional recurrence 6 3
 T recurrence 1 1
 N recurrence 5 2
Median Follow-up 
(months)
38 (95% CI 
30.72-48)
42,50 (95% 
CI 32.72-
49,27)
Total patients 42 42
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HPV and HSV in basaloid tumors than in conventional 
SCC of head and neck especially in some locations like 
nasopharynx, but other authors have not found any 
difference especially in larynx, such as in our experience 
about laryngeal cancer [15, 22, 23, 24]. The supposed 
higher clinical aggressiveness of BSCC compared to the 
conventional SCC is still controversial. Winzenburg et al. 
were the first to correlate some histological variables of 
BSCC to prognosis, reporting that cases with pure basaloid 
histology and comedonecrosis showed distant metastases 
in 46% of the patients. A predominantly basaloid histology 
was associated with distant metastases in 52% of their 
patients [24, 25]. Patients usually present at an advanced 
stage: in fact, some authors reported 76% in Stages III 
or IV at diagnosis, while others described that 36% of 
cases were at Stage III and 41% at Stage IV. Thankappan 
reported 45.9% of nodal metastasis at presentation and no 
distant metastases [16, 26]. Generally, distant metastases 
occur also in 10-75% of BSCCs and lung is the main 
organ for distant metastases in BSCC [27]. Since most 
cases of BSCC occurred in advanced stage, this feature 
is believed to be reflective of tumor aggressiveness and 
poor prognosis [1]. However, with the introduction of new 
treatment modalities for head and neck tumors, the disease-
free time is increased, resulting in a higher detection of 
distant metastases. The incidence of distant metastases in 
patients with laryngeal cancers remains low, with a rate 
of 5% reported by Bahar et al. [18]. On the other hand, 
finding a second primary tumor is not uncommon in head 
and neck BSCC. McKay and Bilous in 1989 reported a 
case of BSCC of the hypopharynx with microinvasive 
squamous cell carcinoma in the arytenoid region [28]. In 
1991 Seidman et al. presented a series of 11 BSCCs, two of 
which (tumors arising in the piriform sinus and vallecula) 
with synchronous SCC in upper gastrointestinal tract 
(oesophagus and palate, respectively) [28, 29]. According 
to Ereno et al., 2008, the incidence of metachronic second 
primary tumors was 15%, 6/40 cases, in details 3 in lung, 3 
in bone and 1 in liver, respectively [15].
In the present study, we have observed second 
primary tumors in 13 out of 42 patients (30.9%) in patients 
with laryngeal BSCC and in 3/42 (7.1%) patients with 
LSCC, particularly in lung and colon. Mortality was 21/42 
in BSCC (50%) and 10/42 in LSCC (23.81%):
∙ 7/21 patients of BSCC (33.33%) died for laryngeal 
cancer;
∙ 12/21 (57.14%) of BSCC died for second tumor;
∙ 2/21 (9.53%) patients of BSCC died for other 
causes.
∙ 3/10 patients of LSCC (30%) died for laryngeal 
cancer;
∙ 3/10 patients of LSCC (30%) died for second 
tumor;
∙ 4/10 patients of LSCC (40%) died for other causes.
Conversely, observed survival was 50% in BSCC 
and 76,19% in LSCC.
According to our results these data were statistically 
relevant; moreover, BSCC had a 4.4-fold higher risk to 
be affected and dying for a second primary tumor than 
Table 2: Univariate analysis of clinical and 
pathological characteristics between the subgroups
Variable Basaloid 
subgroup A
Non-basaloid 
subgroup B
Second tumor 
occurrence
 p value 0.008 0.62
 HR 4.3634 1.4306
 95% CI of HR 1.3265 to 14.3525
0.3459 to 
5.9167
DSS
 p value 0.15 0.5768
 HR 0.49 1.507
 95% CI of HR 0.1807 to 1.3288
0.3596 to 
6.3151
Grading
 p value 0.03 0.5533
 HR 3.9333 1.5246
 95% CI of HR 0.8795 to 17.5909
0.3808 to 
6.1034
Staging
 p value 0.62 0.6302
 HR 0.85 0.7911
 95% CI of HR 0.4473 to 1.6152
0.3062 to 
2.0440
Treatment strategy
 p value 0.45 0.1306
 HR 0.8494 0.6521
 95% CI of HR 0.5638 to1.2795
0.3757 to 
1.1319
Legend: HR, Hazard Ratio; CI, Confidential Interval; 
DSS, Disease-Specific Survival
Table 3: Multiparametric analysis in basaloid 
subgroup
Value Second tumour 
occurrence
Grading
p value 0.0725 0.2915
HR 3.1886 2.4445
95% CI of HR 0.9053 to 11.2306 0.4684 to12.7578
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the patients with LSCC (HR 4.4); when these data were 
statistically corrected for grading the HR reduced to 3.2-
fold, likely because patients with higher grade tumor 
decease before developing a secondary tumor. Regarding 
the grading, patients with laryngeal BSCC had a risk 
to die for laryngeal cancer 3.9-fold higher than patient 
with LSCC; when these data were statistically corrected 
for second tumor the HR reduced to 2.4-fold, probably 
because some patients with high grade laryngeal BSCC 
die for a second tumor. Regarding treatment, in literature 
some authors perform surgery alone in 28.5% of patients 
with BSCC of larynx; combined modality treatment is 
administered in 67% of cases [27]. Total laryngectomy 
is the most common surgical treatment [16]. BSCC 
has a poor prognosis and its invasive growth pattern as 
small solid foci may be misdiagnosed in small biopsies 
[1]. These patterns justify, in our view, radical treatment 
measures. Finally, the currently practiced treatment 
strategies apparently have no effects on the outcome, and 
more specific anti-basaloid chemotherapy medications 
should be developed. There are not statistically significant 
differences between survival in basaloid and non-basaloid 
subgroups for the cancer originating from larynx but in 
basaloid group there was a high death risk for second 
tumors. A high grading was also associated with mortality 
risk.
MATERIALS AND METHODS
Patients
Study population was selected among patients of 
Ear-nose-throat (ENT) Units at Federico II University and 
Cardarelli Hospital, Naples (Italy) from 1st January 2006 to 
31st October 2015. Patients enrolled in the study underwent 
to ENT examination by laryngoscopy, neck and chest 
CT with intravenous contrast, biopsy with histological 
examination that confirmed diagnosis of laryngeal cancer. 
Patients were treated with cordectomy performed with 
CO2 laser aid or open laryngectomy (supraglottic, subtotal 
or total). In post-operative period, patients underwent to 
oncological follow-up, examinations by ENT specialist 
by direct fiber optic laryngoscopy and video recording in 
accordance with the timetable guidelines for each tumor 
stage, annual neck and chest CT and total body PET for 
the control of both loco-regional and distance disease 
recurrence. pTNM analysis was made according to the 
criteria of VII edition of TNM [12]. Patients with follow-
up lower than 12 months were excluded from the study. 
According to these inclusion criteria, the study population 
was formed by 84 cases of laryngeal carcinoma (74M and 
10F) divided into two subgroups: 42 cases of basaloid 
LSCC (A), according to the histological criteria proposed 
by Wain et al. [9], and 42 cases of non-basaloid LSCC 
(B). Population of basaloid subgroup (A) was composed 
by all consecutive cases (42) with definitive diagnosis 
of basaloid carcinoma of larynx (diagnosis relatively 
less frequent) from 1st January 2006 to 31st October 
2015. In order to highlight the features of BSCC, this 
subgroup was compared to the same number of cases of 
non-basaloid squamous infiltrating laryngeal carcinoma 
(B) with negative anamnesis for any other malignant 
tumors and for exposure to environmental risk factors in 
work places. Basaloid and not Basaloid subgroups were 
homogeneous in staging, grading and treatment strategy. 
The demographic characteristics and staging, grading 
and treatment strategies for each subgroup of patients 
are described in Table 3. The study was performed in 
accordance to the guidelines of the Institutional Ethics 
Committee, Italian law, and the Declaration of Helsinki, 
as required for studies based on retrospective analyses on 
routine archival formalin-fixed, paraffin embedded tissue. 
All patients provided a written informed consent regarding 
the use of these data for research puproses.
Statistical analysis
Follow-up period of both subgroups was compared 
through Wilcoxon/Mann-Whitney test for independent 
and non-parametric variables using Med-Calc software, 
version 9.3.7.0. We applied the Kaplan-Meier method, 
normalizing the different categories by the long-rank 
Mantel-Haenszel test, in order to study overall and 
disease specific survival (OS and DSS) in each subgroup 
and to compare them in the two subgroups. Moreover, we 
calculated the additional risk of second tumor occurrence, 
T and N recurrence and mortality in patients with 
basaloid LSCC compared with non-basaloid LSCC by 
Odds Ratio (OR). A Cox proportional hazard model was 
used to study the simultaneous contribution of multiple 
factors to mortality risk. The assessed variables were 
staging, grading, treatment strategies and disease specific 
survival in each subgroup. We performed Multivariate 
Cox regression analysis for significant variables found 
in univariate analysis (second tumor, and grading) to 
underline HR of patients with basaloid LSCC. In each test, 
the p value <0.05 was considered statistically significant.
CONCLUSIONS
BSCC is a tumor characterized by a biphasic pattern 
of growth and has an aggressive clinical behaviour. 
Immunohistochemistry may be helpful in diagnosis. 
Second primary tumors are frequent. In this study, we have 
analyzed pattern of aggressiveness of BSCC of larynx 
compared to LSCC. Second tumor and grading correlated 
to increased mortality risk in univariate analyses only 
in basaloid LSSC (group A). Second tumour occurrence 
together with grading were the only independent 
prognostic factors for patients with basaloid LSCCs, 
and were significantly associated with poor prognosis. 
This correlation was not found, on the other hand, in non 
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basaloid tumours (subgroup B). Presently, the molecular 
bases of the different biological and clinical behaviors 
of the two different histological subtypes are not known 
and this deserves additional investigations. The different 
expression of molecules involved in the regulation 
of cancer cell growth and mestatization (i.e.: p63 and 
cytokeratins) suggests a different molecular feature of this 
tumour.
Finally, due to both BSCC poor prognosis and 
higher risk of second tumour occurrence, a strict follow-
up with advanced imaging techniques (i.e.: total body 
PET-TC) is mandatory and strongly recommended for the 
correct management of these patients.
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